Tirzepatid 45mg*10vials

▎Tirzepatid Structure

▎Tirzepatid Research

What is the research background of Tirzepatid?

Tirzepatid is a synthetic polypeptide drug, and its development stems from a profound understanding of the limitations of existing GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus and obesity. Although GLP-1 receptor agonists have already shown excellent performance in blood glucose control and weight loss, scientists have found that while they activate the GLP-1 receptor, their activation effect on the GIP receptor is relatively weak, which to a certain extent limits the therapeutic effect of the drugs. Therefore, the research and development team is committed to developing a new type of drug that can activate both the GIPR and GLP-1R simultaneously, in the hope of achieving more comprehensive and effective blood glucose control and weight management^[1] .

During the research and development process of Tirzepatid, scientists have carried out a large number of basic research and clinical trials. First of all, in the preclinical research stage, the pharmacodynamic characteristics of Tirzepatid were deeply evaluated through animal experiments, and its potential in blood glucose control and weight loss was verified. The results showed that Tirzepatid could significantly reduce the blood glucose level in animal models and also performed well in weight management. These positive findings laid a solid foundation for the subsequent clinical trials.

Subsequently, Tirzepatid entered the clinical trial stage, including phase I, II, and III trials. In the phase I trial, the safety, tolerability, and pharmacokinetic characteristics of the drug were mainly evaluated, and the results showed that Tirzepatid had good safety and tolerability. The phase II trial further explored the efficacy and safety of different doses of Tirzepatid in patients with type 2 diabetes mellitus, and preliminarily determined its effective dose range. The most crucial phase III clinical trials, such as the SURPASS series of studies, covered a large number of patients with type 2 diabetes mellitus. The results showed that Tirzepatid was significantly superior to existing GLP-1 receptor agonists, such as semaglutide, in reducing blood glucose and weight. This breakthrough result provided strong evidence support for the marketing application of Tirzepatid ^[1].

Tirzepatid is a polypeptide composed of 39 amino acids, in which individual amino acids have been structurally modified to improve its stability and efficacy. This unique structural design enables Tirzepatid to integrate the effects of two incretin hormones, GIP and GLP-1, into a single molecule, and activate the hormone receptors involved in blood glucose control through a dual mechanism of action. Specifically, Tirzepatid can act on both the pancreas and the central nervous system. On the one hand, it promotes insulin secretion and inhibits glucagon release, thereby effectively reducing blood glucose; on the other hand, by delaying gastric emptying and increasing satiety, it reduces appetite and food intake, and thus achieves weight management. This dual mechanism of action gives Tirzepatid unique advantages in the treatment of type 2 diabetes mellitus and obesity, providing patients with a more comprehensive treatment option^[1].

What is the mechanism of action of Tirzepatid?

Tirzepatid lowers blood glucose through multiple mechanisms working together, as follows: Activation of the GLP-1 receptor: Tirzepatid binds to the GLP-1 receptor on pancreatic β cells, mimicking the effect of natural GLP-1. GLP-1 is a hormone produced in the intestine and is crucial for maintaining glucose homeostasis 2. It can promote insulin synthesis, insulin secretion, and glucose sensing, and reduce glucagon secretion to promote satiety and inhibit appetite 2.

This activation can promote insulin secretion. Insulin is the main blood glucose-lowering hormone in the body, which can increase the uptake and utilization of glucose by cells, thereby reducing blood glucose levels. In patients with type 2 diabetes mellitus, insulin secretion is insufficient or the cells' sensitivity to insulin is reduced, leading to an increase in blood glucose. Tirzepatid increases insulin secretion by activating the GLP-1 receptor, which helps to improve blood glucose control. At the same time, the activation of the GLP-1 receptor can also inhibit the release of glucagon. Glucagon usually promotes glycogenolysis and gluconeogenesis in the fasting state, increasing blood glucose production. By inhibiting the effect of glucagon, Tirzepatid further reduces the source of blood glucose, which helps to control blood glucose ^[2](Anonymous, 2023).

Activation of the GIP receptor: Tirzepatid acts on the GIP receptor at the same time. After activation, it can enhance insulin sensitivity and secretion. The GIP receptor is mainly present in tissues such as pancreatic β cells. After activation, through the conduction of the intracellular signaling pathway, insulin secretion is increased, and the cells' responsiveness to insulin is improved, thereby more effectively reducing blood glucose 2. Tirzepatid is the first-in-class dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) analog, approved for the treatment of adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise 2. Tirzepatid is a synthetic chemical structure based on the GIP sequence, composed of a 39-amino acid peptide. It increases insulin secretion, reduces the release of glucagon in a glucose-dependent manner, lowers fasting and postprandial blood glucose levels, promotes satiety, reduces weight, and delays gastric emptying 2.

This dual receptor agonist effect makes Tirzepatid more effective in promoting insulin secretion and inhibiting glucagon release than single GLP-1 receptor agonists ^[2].

Delaying gastric emptying and increasing satiety: Tirzepatid can delay gastric emptying, prolong the residence time of food in the stomach, slow down the absorption rate of nutrients, and thus avoid a sharp increase in postprandial blood glucose. In preclinical and clinical studies, the effect of Tirzepatid on gastric emptying is comparable to that of GLP-1 receptor agonists. In diet-induced obese mice, the degree of delayed gastric emptying by Tirzepatid is similar to that of semaglutide, but these acute inhibitory effects disappear after 2 weeks of treatment. In participants with and without type 2 diabetes mellitus, once-weekly Tirzepatid (≥5 and ≥4.5mg, respectively) delayed gastric emptying after a single dose. In healthy participants, this effect was attenuated after multiple doses of Tirzepatid or dulaglutide^[3] .

At the same time, it can also act on the central nervous system, increase satiety, and reduce appetite and food intake. By controlling diet intake, it indirectly helps to control blood glucose levels, especially suitable for the obesity problem often accompanied by patients with type 2 diabetes mellitus, and helps to improve insulin resistance and the overall metabolic status ^[2].

Improving insulin sensitivity and lipid metabolism: Tirzepatid has been found to increase the level of adiponectin, which is an adipocytokine related to insulin sensitivity. An increase in the level of adiponectin helps to improve insulin sensitivity, making cells more sensitive to insulin, and thus more effectively taking up and utilizing glucose, reducing blood glucose ^[2].

In addition, Tirzepatid can also improve the lipid profile and has a potential protective effect on cardiovascular health. Tirzepatid has been proven to be able to improve blood pressure, reduce low-density lipoprotein (LDL) cholesterol and triglycerides^[4].This further supports its comprehensive benefits in blood glucose management.

Related research

Efficacy on weight management in patients with obesity and type 2 diabetes mellitus: 

Multiple clinical studies have confirmed significant weight loss effects: In a study named "SURMOUNT-2", this trial was a phase 3, double-blind, randomized, placebo-controlled trial conducted in seven countries. Adults (aged ≥18 years) with a body mass index (BMI) of 27 kg/m² or higher and a glycated hemoglobin (HbA₁c) of 7 - 10% were randomly assigned to receive a once-weekly subcutaneous injection of Tirzepatid (10mg or 15mg) or placebo for 72 weeks. The results showed that at week 72, the percentage of weight loss in the Tirzepatid 10mg and 15mg groups was -12.8% and -14.7%, respectively, while that in the placebo group was -3.2%. The estimated treatment differences of Tirzepatid 10mg and 15mg compared with the placebo were -9.6 percentage points and -11.6 percentage points, respectively, both of which were statistically significant (p＜0.0001). In addition, more patients treated with Tirzepatid reached the threshold of a weight loss of 5% or more (79 - 83% vs 32%) ^[5](Garvey W T, 2023). In the "SURMOUNT-2" study, the baseline average weight was 100.7 kg, the BMI was 36.1 kg/m², and the HbA₁c was 8.02%. After 72 weeks of treatment, Tirzepatid not only significantly reduced weight but also played a positive role in blood glucose control ^[5].

Improvement effect on diabetes-related neuropathy: 

Some studies have pointed out that glucagon-like peptide 1 receptor agonists (GLP1-RAs) can reduce the risk of dementia in patients with type 2 diabetes mellitus by improving memory, learning, and overcoming cognitive impairment. As a dual glucose-dependent insulin polypeptide receptor agonist (GIP-RA)/GLP-1RA, Tirzepatid was studied for its effects on markers of neuronal growth (CREB and BDNF), apoptosis (BAX/Bcl2 ratio), differentiation (pAkt, MAP2, GAP43, and AGBL4), and insulin resistance (GLUT1, GLUT4, GLUT3, and SORBS1) in a neuroblastoma cell line (SHSY5Y). The results for the first time emphasized the role of Tirzepatid in activating the pAkt/CREB/BDNF pathway and downstream signaling cascades, as well as its efficacy in neuroprotection. It also showed that Tirzepatid could counteract the effects related to hyperglycemia and insulin resistance at the neuronal level. Therefore, Tirzepatid can improve the neurodegeneration caused by hyperglycemia and overcome neuronal insulin resistance, providing new insights into the improvement of diabetes-related neuropathy^[6] .

Research progress in the treatment of type 2 diabetes mellitus: 

Some studies have pointed out that Tirzepatid, as a new type of hypoglycemic drug, has become the first dual GIP/GLP-1R agonist approved for the treatment of diabetes in the United States. It has been confirmed to have significant blood glucose-lowering and weight loss effects in multiple large-scale clinical trials, and there is evidence that it also has great potential in cardiovascular protection. In addition, the concept of synthetic peptide has opened up many unknown possibilities for Tirzepatid. Ongoing trials (NCT04166773) and evidence suggest that it appears to be a promising drug in the fields of non-alcoholic fatty liver disease (NAFLD), renal and neuroprotection, etc. ^[7].

Long-term effects of Tirzepatide on cardiovascular health: 

Tirzepatid may reduce the risk of cardiovascular diseases by promoting weight loss. A study examined the impact of Tirzepatid on obesity and cardiovascular disease events in American adults^[8] . The study found that among American adults eligible for Tirzepatid treatment, after treatment with 15mg of Tirzepatid, it was estimated that 70.6% and 56.7% of adults had a weight loss of ≥15% and ≥20%, respectively, which meant that the number of obese people decreased by 58.8%. In people without cardiovascular diseases, the estimated 10-year risk of cardiovascular diseases decreased from 10.1% before treatment to 7.7% after treatment, reflecting an absolute risk reduction of 2.4% and a relative risk reduction of 23.6%, which means that 2 million cardiovascular disease events can be prevented within 10 years.

In conclusion, Tirzepatid is a novel dual agonist of GIP and GLP-1 receptors and is of great significance in the treatment of type 2 diabetes mellitus and obesity. It can more effectively promote insulin secretion, inhibit glucagon secretion, precisely regulate blood glucose, reduce the risk of complications, improve the function of pancreatic β cells, and delay the progression of diabetes. It also has a protective effect on the cardiovascular system. In the treatment of obesity, it can effectively reduce food intake, decrease appetite, increase satiety, help obese patients lose weight, and reduce the risk of obesity-related complications. It can also improve insulin resistance and lipid metabolism. In addition, it shows potential in the treatment of metabolic abnormality-related diseases such as non-alcoholic steatohepatitis, sleep apnea syndrome, and heart failure, and can simultaneously improve multiple metabolic indicators, providing a more comprehensive treatment plan. Its once-weekly injection administration method is convenient to use and can improve patients' treatment compliance. By effectively controlling blood glucose and weight and reducing the risk of complications, patients' physical conditions can be significantly improved, their daily activity ability and quality of life can be enhanced, their confidence in disease control can be increased, their psychological burden can be relieved, and their social adaptability can be improved.

About The Author

The above-mentioned materials are all researched, edited and compiled by Cocer Peptides.

Scientific Journal Author

Dr. William T. Garvey is a distinguished scholar and researcher affiliated with multiple prestigious institutions, including the University of Alabama at Birmingham, Aston University, and the Birmingham Veterans Affairs Medical Center. His academic background and professional experience span a wide range of disciplines within the medical and scientific fields. Dr. Garvey has made significant contributions to the fields of endocrinology and metabolism, nutrition and dietetics, biochemistry and molecular biology, as well as general and internal medicine, with a particular focus on the cardiovascular system and cardiology. His work has been widely recognized and honored, notably being named a Highly Cited Researcher in the Cross-Field category for both 2023 and 2024, reflecting the substantial impact and influence of his research on the broader scientific community.

Dr. Garvey's research interests and expertise extend to various aspects of metabolic diseases and their management. He has been actively involved in studying diabetes mellitus, obesity, and their associated complications, aiming to uncover novel therapeutic strategies and improve patient outcomes. His work encompasses basic scientific research, clinical trials, and translational studies, bridging the gap between laboratory findings and real-world medical applications. Through his extensive research, Dr. Garvey has contributed to a deeper understanding of the underlying mechanisms of metabolic disorders and has helped shape clinical guidelines and treatment protocols in the field of endocrinology and metabolism. Dr. William T. Garvey is listed in the reference of citation ^[5].

▎Relevant Citations

[1] Nowak M, Nowak W, Grzeszczak W. Tirzepatid - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes[J]. Endokrynologia Polska, 2022,73(4):745-755.DOI:10.5603/EP.a2022.0029.

[2] Anonymous. Tirzepatid: A Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus: Erratum.[J]. American Journal of Therapeutics, 2023,30(3):e311.DOI:10.1097/MJT.0000000000001634.

[3] Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selectivelong-acting GLP-1 receptor agonists[J]. Diabetes Obesity & Metabolism, 2020,22(10):1886-1891.DOI:10.1111/dom.14110.

[4] Forzano I, Varzideh F, Avvisato R, et al. Tirzepatid: A Systematic Update[J]. International Journal of Molecular Sciences, 2022,23(23).DOI:10.3390/ijms232314631.

[5] Garvey W T, Frias J P, Jastreboff A M, et al. Tirzepatid once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2023,402(10402):613-626.DOI:10.1016/S0140-6736(23)01200-X.

[6] Fontanella R A, Ghosh P, Pesapane A, et al. Tirzepatid prevents neurodegeneration through multiple molecular pathways[J]. Journal of Translational Medicine, 2024,22(1).DOI:10.1186/s12967-024-04927-z.

[7] Ma Z, Jin K, Yue M, et al. Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatid, a Rising Star in Type 2 Diabetes[J]. Journal of Diabetes Research, 2023,2023.DOI:10.1155/2023/5891532.

[8] Wong N D, Karthikeyan H, Fan W. US Population Eligibility and Estimated Impact of Tirzepatid Treatment on Obesity Prevalence and Cardiovascular Disease Events[J]. Cardiovascular Drugs and Therapy, 2024.DOI:10.1007/s10557-024-07583-z.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  

The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.